Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus PARADIONE.
DIACOMIT vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
12-24 hours (terminal); prolonged in renal impairment
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant